nociceptin (113) amide tfa

Nociceptin (1-13), amide is a potent agonist Opioid receptor-like1 (ORL1) receptor with a pEC50 of 7.9 for mouse vas deferens and a Ki of 0.75 nM for binding to rat forebrain membranes.

2-Furoyl-LIGRLO-amide TFA(729589-58-6 free base) is a potent and selective protease-activated receptor 2 (PAR2) agonist.

[Met5]-Enkephalin, amide TFA (5-Methionine-enkephalin amide (TFA)) is a δ opioid receptors agonist as well as putative ζ (zeta) opioid receptors.

Acetyl-PHF6 amide TFA is a tau derived hexapeptide.

GLP-1 (1-36) amide (human, rat) TFA, a molecular variant of GLP-1 (7-36) amide, can induce [14C]aminopyrine accumulation in enzymatically dispersed enriched rat parietal cells [1].

GIP (1-30) amide (Human) TFA is a glucose-dependent insulinotropic polypeptide fragment. Glucose-dependent insulinotropic polypeptide (GIP) is an incretin hormone that stimulates insulin secretion and reduces postprandial glycaemic excursions.

Amylin, amide, human TFA, a 37-amino acid polypeptide, functions as a pancreatic hormone that is cosecreted with insulin, playing distinct roles in metabolism and glucose homeostasis. It regulates blood sugar by inhibiting glucagon secretion, delaying gastric emptying, and promoting satiety [1].

Nociceptin (1-13), amide is a potent ORL1 (OP4) receptor agonist with a pEC50 of 7.9 for mouse vas deferens and a Ki of 0.75 nM for binding to rat forebrain membranes.

[Arg8]-Vasotocin (TFA) is a nonmammalian vertebrate neurohypophyseal peptide.

GLP-1(32-36)amide TFA, originating from the C-terminal end of the glucoregulatory hormone GLP-1, is a pentapeptide that has demonstrated the ability to mitigate weight gain and regulate glucose metabolism throughout the body in diabetic mice [1] [2].

TRAP-6 amide TFA is a PAR-1 thrombin receptor agonist peptide.

PKI (14-24)amide TFA, a potent inhibitor of Protein Kinase A (PKA), significantly reduces cyclic AMP-dependent protein kinase activity within cellular homogenates, as evidenced by research findings [1] [2].

GLP-1(28-36)amide TFA, a C-terminal nonapeptide derived from GLP-1 cleavage by neutral endopeptidase (NEP), acts as an antioxidant targeting mitochondria. It inhibits mitochondrial permeability transition (MPT), exhibiting anti-diabetic and cardioprotective effects [1].

GLP-1(9-36)amide TFA, a predominant metabolite of glucagon-like peptide-1-(7-36)amide synthesized through dipeptidyl peptidase-4 (DPP-4) activity, functions as an antagonist to the human pancreatic GLP-1 receptor [1] [2].

Neuropeptide Y (29-64), amide, human (TFA) is involved in Alzheimer's disease (AD) and protects rat cortical neurons against β-Amyloid toxicity.It is showed that Neuropeptide Y (29-64), amide, human (TFA) is able to protect cortical neurons from Aβ25-35 t

[Nphe1]Nociceptin(1-13)NH2 is a novel endogenous ligand for the nociceptin/orphanin FQ (NC) receptor, acting as a selective and competitive antagonist without any agonist effects. It binds specifically to recombinant nociceptin receptors with high affinity (pKi=8.4) and effectively blocks nociceptin's ability to inhibit cyclic AMP accumulation in CHO cells (pA2=6.0), showcasing potential as an analgesic agent.

GIP (1-30) amide, porcine TFA is a high-affinity full agonist of the glucose-dependent insulinotropic polypeptide (GIP) receptor, having a similar potency as the native GIP(1-42) [1]. Furthermore, GIP (1-30) amide, porcine displays weak inhibitory effects on gastric acid secretion while exhibiting potent insulin-stimulating properties.

[Des-His1,Glu9]-Glucagon amide TFA is a potent peptide antagonist targeting the glucagon receptor, featuring a pA2 value of 7.2. It holds potential utility in diabetes pathogenesis research[1].

PKI 14-22 amide, myristoylated TFA is a potent inhibitor of cAMP-dependent protein kinase A (PKA) that diminishes IgG-mediated phagocytic response and inhibits neutrophil adhesion [1].

[Arg14,Lys15]Nociceptin TFA is a potent and selective agonist for the NOP receptor (ORL1; OP4), exhibiting an EC50 of 1 nM. It demonstrates significant selectivity against opioid receptors, with IC50 values of 0.32 nM for NOP, and 280, >10000, and 1500 nM for μ, δ, and κ receptors, respectively [1].

Nociceptin (1-13), amide TFA, a potent ORL1 receptor (opioid receptor-like 1 receptor, OP4) agonist, exhibits a pEC 50 of 7.9 in mouse vas deferens and a K i of 0.75 nM for rat forebrain membrane binding [1] [2].

Nociceptin (1-7) TFA, the N-terminal bioactive fragment of nociceptin, serves as a potent ORL 1 (NOP) receptor agonist, exhibiting antinociceptive properties. Its combination with nociceptin effectively reduces hyperalgesia in vivo [1].

GLP-1(7-36), amide TFA is a prominent intestinal hormone known to stimulate glucose-induced insulin secretion from β cells[1].

TAT-amide TFA is a cell penetrating peptide. The cell - penetrating peptides (CPPs) is a kind of access to the short amino acid sequence of different cells.

Acetyl-PHF6 amide TFA (AcPHF6 TFA) is a tau derived hexapeptide.

PAR-4 Agonist Peptide, amide TFA (PAR-4-AP (TFA)), is a selective activator of the proteinase-activated receptor-4 (PAR-4), demonstrating specificity by not influencing PAR-1 or PAR-2, and its activity can be inhibited by a PAR-4 antagonist.

PKA Inhibitor Fragment (6-22) amide TFA (PKA Inhibitor Fragment (6-22) amide TFA) is an inhibitor of the highly potent cAMP-dependent protein kinase A (PKA) inhibitor (Ki: 2.8 nM).PKA Inhibitor Fragment (6-22) amide TFA reverses the pain-relieving effects of low levels of morphine in mice.